SCHEMBL5451786

SCHEMBL5451786

CC(C)Cn1c(CN(C(=O)O)C(C)(C)C)nc2cnc3ccccc3c21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.39
NPSR1 Q6W5P4 4/20 0.39
ALDH1A1 P00352 7/20 0.38
SMN1; SMN2 Q16637 5/20 0.38
CASP1 P29466 2/20 0.38
TSHR P16473 2/20 0.38
TLR7 Q9NYK1 5/20 0.38
TLR8 Q9NR97 1/20 0.38
HTT P42858 1/20 0.38
CASP7 P55210 1/20 0.38
HSD17B10 Q99714 1/20 0.38
POLB P06746 1/20 0.36
HRH2 P25021 1/20 0.36
ADRA1D P25100 1/20 0.36
HTR2A P28223 1/20 0.36
ADORA2A P29274 1/20 0.36
ADRA1A P35348 1/20 0.36
NUDT1 P36639 1/20 0.36
HTR2B P41595 1/20 0.36
PDE4D Q08499 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5459032 0.83 TLR7 (0.59) LMNATLR7TLR8POLBHRH2
SCHEMBL6726435 0.80 LMNA (0.42) LMNANPSR1ALDH1A1SMN1; SMN2TSHR
SCHEMBL5808827 0.80 LMNA (0.53) LMNANPSR1ALDH1A1SMN1; SMN2TLR7
SCHEMBL6719567 0.79 TLR7 (0.43) LMNANPSR1ALDH1A1SMN1; SMN2TSHR
SCHEMBL1490528 0.78 LMNA (0.38) LMNANPSR1ALDH1A1SMN1; SMN2TLR7
SCHEMBL5808831 0.78 ALDH1A1 (0.42) LMNANPSR1ALDH1A1SMN1; SMN2TSHR
SCHEMBL10589469 0.78 TLR7 (0.52) LMNANPSR1ALDH1A1SMN1; SMN2TSHR
SCHEMBL8565615 0.78 TSHR (0.47) LMNANPSR1ALDH1A1SMN1; SMN2TSHR
SCHEMBL6723871 0.77 TLR7 (0.52) LMNANPSR1ALDH1A1SMN1; SMN2TSHR
SCHEMBL1490913 0.77 LMNA (0.37) LMNANPSR1TSHRTLR7MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070259881-A1 Substituted Imidazo Ring Systems and Methods COLEY PHARMACEUTICAL GROUP, INC. 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259881-A1 Substituted Imidazo Ring Systems and Methods IL2, IL4, IRF3 LMNA 4207/4885NPSR1 3420/4885ALDH1A1 2134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.